Celldex Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $7.0M | $6.9M | $2.4M | $4.7M | $7.4M | $3.6M | $9.5M |
| Cost of Revenue | $200.0K | $200.0K | $300.0K | $100.0K | $100.0K | $200.0K | $100.0K | $700.0K |
| Gross Profit | $1.3M | $6.8M | $6.6M | $2.3M | $4.6M | $7.2M | $3.5M | $8.8M |
| Gross Margin | 87.1% | 97.2% | 95.6% | 95.8% | 97.8% | 97.3% | 97.2% | 92.7% |
| Operating Expenses | ||||||||
| Research & Development | $245.1M | $163.6M | $118.0M | $82.3M | $53.3M | $42.5M | $42.7M | $66.4M |
| SG&A Expense | $43.8M | $38.5M | $30.9M | $27.2M | $20.5M | $14.5M | $15.4M | $19.3M |
| Operating Income | $-287.4M | $-195.1M | $-154.5M | $-115.2M | $-71.2M | $-63.4M | $-55.0M | $-156.4M |
| Operating Margin | -18,599.8% | -2,778.9% | -2,245.3% | -4,889.0% | -1,531.8% | -854.1% | -1,540.2% | -1,640.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-258.8M | $-157.9M | $-141.4M | $-112.3M | $-70.7M | $-60.9M | $-50.9M | $-151.9M |
| Income Tax Expense | $0 | $0 | $0 | — | $-227.0K | $-1.2M | — | $-765.0K |
| Net Income | $-258.8M | $-157.9M | $-141.4M | $-112.3M | $-70.5M | $-59.8M | $-50.9M | $-151.2M |
| Net Margin | -16,748.0% | -2,248.8% | -2,054.8% | -4,765.6% | -1,516.0% | -805.9% | -1,424.0% | -1,585.1% |
| EPS (Basic) | $-3.90 | $-2.45 | $-2.92 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.01 |
| EPS (Diluted) | $-3.90 | $-2.45 | $-2.92 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.01 |
| Shares Outstanding (Basic) | 66.4M | 64.4M | 48.4M | 48.4M | 44.3M | 30.6M | 30.0M | 24.70B |
| Shares Outstanding (Diluted) | 66.4M | 64.4M | 48.4M | 48.4M | 44.3M | 30.6M | 30.0M | 24.70B |
| Dividends Per Share | — | — | — | — | — | — | — | — |